Vesalius bags €65M biotech fund while Novartis vet Guidi canvases for a €50M gamble on Italian scientists
The Luxembourg-based biotech venture firm Vesalius Biocapital has raised more than €65 million for its third fund, which will remain open in search of additional cash.
Vesalius has been broadening its horizons beyond late-stage European investments in drug development, medtech, diagnostics and eHealth/mHealth, opening an office in Boston to see if it can get in on some of the US syndicates.
Vesalius has enjoyed a few significant exits recently, including Ogeda (acquired by Astellas for €800 million), Activaero (sold to Vectura for €130 million), Genkyotex (reverse merger on Euronext) and Fovea (acquired by Sanofi for €370 million).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.